We’re here to help you, your staff, and families living with CPP every step of the way

Triptodur CareSM Resources:
Enroll your patients today

Download these resources to get started:

Patient Enrollment Form (English)

Patient Enrollment Form (Spanish)

Triptodur Care Program Summary and FAQ

Request Additional Materials and Support Services

Copay Reimbursement Form

Copay Reimbursement Process

In-Home Nurse Injection Program Enrollment Form

Triptodur Care Patient Assistance Program Form

Triptodur Care Bridge Program Form

Administration Resources

These resources will help you understand the full process of reconstitution and administration prior to injection

Download the Triptodur Administration Guide for full information on reconstitution and administration, including helpful tips.

Watch the Triptodur Administration Video, which provides step-by-step instructions for reconstitution and administration in an easy-to-follow visual format.

Request virtual or live in-service support for Triptodur administration by completing this form.

Patient and Caregiver Resources

Meet Trip the Dino. Trip is here to support you and your child on your journey with Triptodur, along with additional helpful materials.

Triptodur Patient Welcome Kit that includes Trip the Dino, a supportive stuffed animal, Trip and Growing Up Ahead of Schedule Storybook, and caregiver educational materials all delivered in a Triptodur bag.

Trip and Growing Up Ahead of Schedule Storybook (English/Spanish/Chinese) and video series. Follow the lovable dinosaur as Trip learns about what CPP is and what to expect with treatment with Triptodur.

Caregiver Brochure with more about CPP, treatment with Triptodur, and tips on talking to your child about CPP (English/Spanish).

Medical Billing Resources

Download these forms for coding and billing guidance to avoid potential issues before they happen.

Checklist for Prior Authorization Submission

Product Fact Sheet (Billing Units Included)

Sample Letter of Medical Necessity

Sample CMS 1450 Form

Sample CMS 1500 Form

Support and Materials Request

If you need anything else, complete our Materials and Support Services Request Form.

IMPORTANT SAFETY INFORMATION FOR TRIPTODUR

INDICATION

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).

IMPORTANT SAFETY INFORMATION

Contraindications

TRIPTODUR is contraindicated in:

  • Individuals with a known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH.
  • Women who are or may become pregnant. Expected hormonal changes that occur with TRIPTODUR treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential risk to the fetus.

Warnings and Precautions

Initial Rise of Gonadotropins and Sex Steroid Levels – During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug. Therefore, a transient increase in clinical signs and symptoms of puberty, including vaginal bleeding, may be observed during the first weeks of therapy or after subsequent doses.

Psychiatric Events – Psychiatric events have been reported in patients taking GnRH agonists. Postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment with TRIPTODUR.

Convulsions – Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists, including triptorelin. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above.

Pseudotumor Cerebri (idiopathic intracranial hypertension) – has been reported in pediatric patients receiving GnRH agonists, including triptorelin. Monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea.

Adverse Reactions

In clinical trials for TRIPTODUR, the most common adverse reactions (≥4.5%) are injection site reactions, menstrual (vaginal) bleeding, hot flush, headache, cough, and infections (bronchitis, gastroenteritis, influenza, nasopharyngitis, otitis externa, pharyngitis, sinusitis, and upper respiratory tract infection).

To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The Important Safety Information does not include all the information needed to use TRIPTODUR safely and effectively. For additional safety information, please consult the full Prescribing Information for TRIPTODUR.